Why the study?
The role of clinical and biochemical markers in predicting one-year outcomes after primary PCI for STEMI required determination.
Do MMP-9 levels and EQ-5D scores predict a composite one-year endpoint in patients with STEMI after primary PCI?
Cohort (n=44)
No
Do MMP-9 levels and EQ-5D scores predict a composite one-year endpoint in patients with STEMI after primary PCI?
Answers are grounded in this paper and cite their sources.
Elevated MMP-9 (>194 ng/ml) and lower EQ-5D scores (<55 points) on admission are significant predictors of major adverse cardiovascular events at 1 year in patients with STEMI undergoing primary PCI.
OBJECTIVE: Aim of our study was to determine the role of the clinical and biochemical markers in predicting the outcomes at one year in patients with STEMI who have undergone primary PCI. PATIENTS AND METHODS: Materials and methods: The study included 165 patients admitted with STEMI within 12 hours of the onset of symptoms be¬tween January 2020 and August 2021. All patients underwent primary PCI according to the guidelines, followed by standard examination and treatment at the hospital. Blood samples for biomarker analysis (MMP-9, cTnI) and other routine tests were taken on admission. At six months after the event, all patients underwent clinical follow-up. Patients were contacted either by phone, through family members or their physicians 1 year after the event. RESULTS: Results: The composite endpoint reached 9% of patients at one-year follow-up. ROC analysis of MMP-9 with the one-year com¬posite endpoint showed an AUC=0.711, with 91.7% sensitivity, and 47.4% specificity, 95% CI - 0.604 to 0.802, p=0.0037. ROC analysis of EQ-5D questionnaire with the one-year composite endpoint showed AUC = 0.73, the 95% CI - 0.624 to 0.820, p< 0.0195, with sensitivity 54.5% and specificity 94.7%. A logistic regression model showed a statistical association with the com¬posite endpoint at one year after STEMI in both EQ-5D (OR=0.89, 95% CI: 0.8313- 0.9725, p=0.0079) and MMP-9 (OR=1.0151, 95% CI:1.0001-1.0304, p=0.0481). CONCLUSION: Conclusions: The level of MMP-9 more than 194 ng/ml and <55 points in EQ-5D predicts major adverse cardiovascular events, in¬cluding cardiovascular mortality and progressive heart failure, as well as other elements of composite endpoints, during a 1-year follow-up in patients with STEMI after primary PCI. Future studies are needed to clarify this result.
No takes yet. Share an insight, caveat, or question.
Vyshnevska et al. (2023) conducted a cohort in Post-COVID depression (n=44). Escitalopram was evaluated on Depression severity level on the Hamilton Depression Scale (HAM-D) (MD -14.21, 95% CI -15.36 to -13.05, p=<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: